Related Experiment Videos
Radical retropubic prostatectomy: time trends, morbidity and mortality in Japan
Prostate Cancer and Prostatic Diseases
|December 24, 2002
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology·2015
Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
International journal of urology : official journal of the Japanese Urological Association·2000
Radical retropubic prostatectomy: time trends, morbidity and mortality in Japan.
BJU international·2000
[Concurrent platinum-based chemotherapy and radiotherapy for locally advanced bladder cancer].
Hinyokika kiyo. Acta urologica Japonica·2000
[Bilateral synchronous renal cell carcinoma: report of three cases].
Hinyokika kiyo. Acta urologica Japonica·1999
[Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT].
Gan to kagaku ryoho. Cancer & chemotherapy·1999
Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer.
Prostate cancer and prostatic diseases·2026
Oncological and functional outcomes of focal irreversible electroporation for localised prostate cancer: a single institution series of 171 cases.
Prostate cancer and prostatic diseases·2026
Correlation of intraprostatic lesional SUVmax during PSMA PET/CT and adverse pathology at radical prostatectomy.
Prostate cancer and prostatic diseases·2026
Prostate size and its effect on sexual function following convective water vapor thermal therapy.
Prostate cancer and prostatic diseases·2026
Successful cabazitaxel desensitization after severe taxane hypersensitivity reactions: a brief report.
Prostate cancer and prostatic diseases·2026
Utilization patterns of second-generation androgen receptor pathway inhibitors as first-line therapy for prostate cancer in the United States.
Prostate cancer and prostatic diseases·2026
Discontinuing extended-release buprenorphine: Participant experiences from a mixed-methods observational study.
Drug and alcohol dependence reports·2026